Canagliflozin Attenuates the Progression of Atherosclerosis and Inflammation Process in APOE Knockout Mice

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2018 Jul 28

PMID 30049285

Citations 74

Authors

Narjes Nasiri-Ansari

Georgios K Dimitriadis

Georgios Agrogiannis

Despoina Perrea

Ioannis D Kostakis

Gregory Kaltsas

Athanasios G Papavassiliou

Harpal S Randeva

Eva Kassi

Affiliations

Soon will be listed here.

Abstract

Background: Sodium glucose co-transporter2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with canagliflozin on biochemical and immunohistochemical markers related to atherosclerosis and atherosclerosis development in the aorta of apolipoprotein E knockout (Apo-E) mice.

Methods: At the age of 5 weeks, mice were switched from normal to a high-fat diet. After 5 weeks, Apo-E mice were divided into control-group (6 mice) treated with 0.5% hydroxypropyl methylcellulose and Cana-group (7 mice) treated with canagliflozin (10 mg/kg per day) per os. After 5 weeks of intervention, animals were sacrificed, and heart and aorta were removed. Sections stained with hematoxylin-eosin (H&E) were used for histomorphometry whereas Masson's stained tissues were used to quantify the collagen content. Immunohistochemistry to assess MCP-1, CD68, a-smooth muscle actin, MMP-2, MMP-9, TIMP-1 and TIMP-2 expression was carried out and q-PCR experiments were performed to quantify mRNA expression.

Results: Canagliflozin-group mice had lower total-cholesterol, triglycerides and glucose levels (P < 0.01), while heart rate was significantly lower (P < 0.05). Histomorphometry revealed that one in seven Cana-group mice versus four in six control mice developed atheromatosis, while aortic root plaque was significantly less, and collagen was 1.6 times more intense in canagliflozin-group suggesting increased plaque stability. Immunohistochemistry revealed that MCP-1 was significantly less expressed (P < 0.05) in the aortic root of canagliflozin-group while reduced expression of a-actin and CD68 was not reaching significance (P = 0.15). VCAM-1 and MCP-1 mRNA levels were lower (P = 0.02 and P = 0.07, respectively), while TIMP-1/MMP-2 ratio expression was higher in canagliflozin-group approaching statistical significance (P = 0.07).

Conclusions: Canagliflozin attenuates the progression of atherosclerosis, reducing (1) hyperlipidemia and hyperglycemia, and (2) inflammatory process, by lowering the expression of inflammatory molecules such as MCP-1 and VCAM-1. Moreover, canagliflozin was found to increase the atherosclerotic plaque stability via increasing TIMP-1/MMP-2 ratio expression.

Citing Articles

Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes.

Piccirillo F, Lanciotti M, Nusca A, Frau L, Spano A, Liporace P Int J Mol Sci. 2025; 26(5).

PMID: 40076724 PMC: 11899902. DOI: 10.3390/ijms26052103.

Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages.

Rykova E, Klimontov V, Shmakova E, Korbut A, Merkulova T, Kzhyshkowska J Int J Mol Sci. 2025; 26(4).

PMID: 40004134 PMC: 11854991. DOI: 10.3390/ijms26041670.

Effect of sodium glucose cotransporter 2 inhibitors on all cause death and rehospitalization for heart failure in patients with acute myocardial infarction.

Xiong B, He L, Zhang A, Ling Z Sci Rep. 2024; 14(1):30148.

PMID: 39627297 PMC: 11615227. DOI: 10.1038/s41598-024-81954-2.

The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives-A Narrative Review.

Miceli G, Basso M, Pennacchio A, Cocciola E, Pintus C, Cuffaro M Medicina (Kaunas). 2024; 60(11).

PMID: 39596981 PMC: 11596194. DOI: 10.3390/medicina60111796.

The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease.

Hershenson R, Nardi-Agmon I, Leshem-Lev D, Kornowski R, Eisen A Cardiovasc Diabetol. 2024; 23(1):386.

PMID: 39468546 PMC: 11520434. DOI: 10.1186/s12933-024-02466-x.

References

Harrington J . The role of MCP-1 in atherosclerosis. Stem Cells. 2000; 18(1):65-6. DOI: 10.1634/stemcells.18-1-65. View

Werle M, Schmal U, Hanna K, Kreuzer J . MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells. Cardiovasc Res. 2002; 56(2):284-92. DOI: 10.1016/s0008-6363(02)00600-4. View

Wholey M, Wholey M . Current status in cervical carotid artery stent placement. J Cardiovasc Surg (Torino). 2003; 44(3):331-9. View

Deem T, Cook-Mills J . Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species. Blood. 2004; 104(8):2385-93. PMC: 2710031. DOI: 10.1182/blood-2004-02-0665. View

McLennan S, Wang X, Moreno V, Yue D, Twigg S . Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology. 2004; 145(12):5646-55. DOI: 10.1210/en.2004-0436. View

Hansson G, Libby P . The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6(7):508-19. DOI: 10.1038/nri1882. View

Siani A, Strazzullo P, Giorgione N, De Leo A, Mancini M . Insulin-induced increase in heart rate and its prevention by propranolol. Eur J Clin Pharmacol. 1990; 38(4):393-5. DOI: 10.1007/BF00315583. View

Li J, Wang Q, Chai W, Chen M, Liu Z, Shi W . Hyperglycemia in apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility. Cardiovasc Diabetol. 2011; 10:117. PMC: 3273441. DOI: 10.1186/1475-2840-10-117. View

Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T . Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012; 7(2):e30555. PMC: 3280264. DOI: 10.1371/journal.pone.0030555. View

10.

Li H, Peng W, Jian W, Li Y, Li Q, Li W . ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion. Cardiovasc Diabetol. 2012; 11:65. PMC: 3461463. DOI: 10.1186/1475-2840-11-65. View

11.

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y . Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013; 715(1-3):246-55. DOI: 10.1016/j.ejphar.2013.05.014. View

12.

Cefalu W, Leiter L, Yoon K, Arias P, Niskanen L, Xie J . Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382(9896):941-50. DOI: 10.1016/S0140-6736(13)60683-2. View

13.

Chen M, Yi L, Jin X, Xie Q, Zhang T, Zhou X . Absorption of resveratrol by vascular endothelial cells through passive diffusion and an SGLT1-mediated pathway. J Nutr Biochem. 2013; 24(11):1823-9. DOI: 10.1016/j.jnutbio.2013.04.003. View

14.

Allahverdian S, Chehroudi A, McManus B, Abraham T, Francis G . Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation. 2014; 129(15):1551-9. DOI: 10.1161/CIRCULATIONAHA.113.005015. View

15.

Yang C, Li W, Li S, Li J, Li Y, Kong S . MCP-1 stimulates MMP-9 expression via ERK 1/2 and p38 MAPK signaling pathways in human aortic smooth muscle cells. Cell Physiol Biochem. 2014; 34(2):266-76. DOI: 10.1159/000362997. View

16.

Oelze M, Kroller-Schon S, Welschof P, Jansen T, Hausding M, Mikhed Y . The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 2014; 9(11):e112394. PMC: 4234367. DOI: 10.1371/journal.pone.0112394. View

17.

Shankman L, Gomez D, Cherepanova O, Salmon M, Alencar G, Haskins R . KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med. 2015; 21(6):628-37. PMC: 4552085. DOI: 10.1038/nm.3866. View

18.

Terasaki M, Hiromura M, Mori Y, Kohashi K, Nagashima M, Kushima H . Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice. PLoS One. 2015; 10(11):e0143396. PMC: 4659635. DOI: 10.1371/journal.pone.0143396. View

19.

Kassi E, Nasiri-Ansari N, Spilioti E, Kalotychou V, Apostolou P, Moutsatsou P . Vitamin D interferes with glucocorticoid responsiveness in human peripheral blood mononuclear target cells. Cell Mol Life Sci. 2016; 73(22):4341-4354. PMC: 11108367. DOI: 10.1007/s00018-016-2281-3. View

20.

Ruddy J, Ikonomidis J, Jones J . Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability. J Vasc Res. 2016; 53(1-2):1-16. PMC: 7196926. DOI: 10.1159/000446703. View